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Background: The protective effect of HDL is mostly attributed to their metabolic function in reverse cholesterol
transport (RCT), a process whereby excess cellular cholesterol is taken up from peripheral cells, processed in HDL
particles, and later delivered to the liver for further metabolism and biliary secretion. Mechanistically, the purinergic
P2Y13 ADP-receptor is involved in hepatic HDL endocytosis (i.e., uptake of both HDL protein + lipid moieties), which
is considered an important step of RCT. Accordingly, chow-fed P2Y13 knockout (P2Y13
−/−) mice exhibit lower hepatic
HDL uptake, which translates into a decrease of hepatic free cholesterol content and biliary cholesterol and
phospholipid secretion.
Findings: The aim of this study was to determine the effect of high cholesterol diet (HCD) in P2Y13
−/− mice, in
order to mimic high dietary cholesterol intake, which is a major cause of dyslipidemia in humans. As previously
reported with chow-diet, HCD did not affect plasma lipid levels in P2Y13
−/− compared with control mice but
decreased hepatic free and esterified cholesterol content (p < 0.05, P2Y13
−/− versus control). Interestingly, biliary
lipid secretion and macrophages-to-feces RCT were more dramatically impaired in P2Y13
−/− mice fed a HCD than
chow-diet. HCD did not enhance atherosclerosis in P2Y13
−/− compared with control mice.
Conclusion: This study demonstrates that high dietary cholesterol intake accentuated the metabolic phenotype of
P2Y13
−/− mice, with impaired hepatobiliary RCT. Although other animal models might be required to further
evaluate the role of P2Y13 receptor in atherosclerosis, P2Y13 appears a promising target for therapeutic intervention
aiming to stimulate RCT, particularly in individuals with lipid-rich diet.
Keywords: P2Y13, HDL, HDL-uptake, High cholesterol diet, Bile lipid secretions, Reverse cholesterol transport,
Cholesterol metabolism, Liver, ATP synthaseFindings
Introduction/research hypothesis
Dyslipidemia, reflected by either high triglyceride or
cholesterol plasma concentrations, is a major risk factor
of atherosclerosis [1]. The risk of atherosclerosis, a leading
cause of cardiovascular disease and death, is inversely* Correspondence: Laurent.Martinez@inserm.fr.
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distribution, and reproduction in any mediumcorrelated to plasma high-density lipoprotein cholesterol
(HDL-C). The protective effect of HDL particles is mostly
attributed to their central function in Reverse Cholesterol
Transport (RCT), a process whereby peripheral excessive
cholesterol, especially that contained in macrophage foam
cells, is taken up to be processed in HDL particles, and
later delivered to the liver for final excretion into the feces
either as neutral sterols or after metabolic conversion
into bile acids [2]. This process, which represents a
major pathway of the body to eliminate proatherogenic
cholesterol, relies on specific interactions between HDLntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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hepatic cells (cholesterol output). We recently identified
a new pathway for holoparticle HDL endocytosis by the
liver (i.e., hepatic uptake of both HDL protein + lipid
moieties), involved in RCT. In this pathway, apoA-I, the
major protein of HDL, binds an ecto-F1-ATPase leading to
ATP hydrolysis into ADP [3]. Extracellular ADP activates
the purinergic P2Y13 ADP-receptor, which stimulates
in fine HDL uptake through an unknown low affinity
receptor, distinct from the classical HDL receptor, SR-BI.
Our recent work has confirmed the role of the P2Y13
receptor in HDL-mediated RCT in vivo [4]. We showed
that P2Y13-deficient mice (P2Y13
−/−) exhibited a decrease
in hepatic HDL uptake, hepatic cholesterol content, and
biliary cholesterol output, although their plasma HDL-C
and other lipid levels were normal. These metabolic
changes translated into a substantial decrease in the rate
of macrophage-to-feces RCT. Therefore, key features of
RCT were impaired in P2Y13
−/− mice.
In order to investigate the role of P2Y13 in a dyslipidemic
context, we studied the phenotype of P2Y13
−/− mice fed
high cholesterol diet (HCD) for 16 weeks. Our results show
that chronically increased cholesterol intake accentuates
the metabolic phenotype of P2Y13
−/− mice, with impaired
hepatobiliary metabolism. Specifically, (i) hepatic HDL
uptake mediated by P2Y13 receptor plays an important role
in regulating liver cholesterol content, (ii) P2Y13 receptor
is essential for normal biliary lipid secretion and fecal
excretion of cholesterol originating from macrophages,
(iii) these effects of P2Y13 activity on the flux of HDL
toward the liver does not affect HDL-C level per se or
selected HDL functions. Overall, this work emphasizes the
essential role of P2Y13 in RCT in a dyslipidemic context.
Materials and methods
Animals and diets
The animals were caged in an animal facility with alter-
nating 12 h periods of light (07:00 am-7:00 pm) and
dark (7:00 pm-07:00 am). 8 week-old male P2Y13
−/−
and P2Y13
+/+ littermates mice (C57BL/6 background)
were fed for 16 weeks a high cholesterol diet (Harlan TD
96335, 1.25% cholesterol) then used for experimentation.
All animal procedures were in accordance with the guide-
lines of the Committee on Animals of the Midi-PyrénéesTable 1 Plasma lipid values in P2Y13





TC (mg/dl) 14.1 ± 1.92 12.2 ± 3.42 25.1 ± 1
FC (mg/dl) 4.55 ± 0.71 3.31 ± 0.76 10.3 ± 4
EC (mg/dl) 9.86 ± 1.48 8.93 ± 2.65 14.8 ± 3
TG (mg/dl) 24.6 ± 1.27 23.5 ± 4.52 7.26 ± 1
Values are expressed as means ± SEM; n = 4 mice per group.Ethics Committee on Animal Experimentation and with
the French Ministry of Agriculture license.Plasma lipoprotein analyses
Plasma samples were collected at 11 am, after a fasting
period of 3 h. Total cholesterol and triglycerides were
measured with commercial kits (CHOD-PAP for chol-
esterol and GPO-PAP for triglycerides; BIOLABO SA,
Maizy, France). Quantification of plasma lipoproteins
was performed using an Ultimate® 3000 HPLC system
(Dionex, USA) as previously described [5].Hepatic lipid analyses
Hepatic cholesterol and triglycerides were analyzed,
following Bligh & Dyer lipid extraction, by gas–liquid
chromatography, as previously described [4].Cannulation of the common bile duct and bile lipid
analysis
Mice were fasted for 3 hours and were then anesthetized
by intra-peritoneal injection of ketamine hydrochloride
and xylazine hydrochloride. At 11 am, gallbladder was
cannulated and bile was harvested for 30 minutes, after
a stabilization time of 30 minutes. Bile acid, phospholipid
and cholesterol analysis was performed as previously
reported [5].In vivo macrophage-to-feces RCT
RCT assay was performed as previously described [4].
Briefly, thioglycollate-elicited mouse peritoneal macro-
phages, harvested from C57BL/6(J) donor mice, were
loaded for 24 hours with 50 μg/mL acetylated LDL and
5 μCi / ml 3H-cholesterol, then injected intraperitoneally
in recipient mice (two million dpm/mouse). Blood samples
were taken 6, 24 and 48 hours after macrophages injection,
feces were collected continuously for 48 hours and livers
were harvested 48 hours after macrophages injection and
stored at −80°C until lipid extraction and radioactivity
counting [4]. All counts were expressed as a percentage of





.31 18.5 ± 0.34 85.01 ± 16.9 90.62 ± 8.88
.57 6.00 ± 0.20 33.58 ± 2.56 29.45 ± 2.80
.06 12.5 ± 0.29 53.33 ± 14.2 61.49 ± 6.1
.05 9.43 ± 1.66 6.75 ± 2.23 2.45 ± 0.27
Table 2 Hepatic lipid values in P2Y13
+/+ (WT) and P2Y13
−/−
mice fed a HCD for 16 weeks
WT P2Y13
−/−
Total cholesterol (nmol/mg) 67.11 ± 3.84 50.50 ± 2.53*
Free cholesterol (nmol/mg) 13.28 ± 0.96 9.65 ± 0.54*
Esterified cholesterol (nmol/mg) 53.41 ± 3.37 41.97 ± 1.89*
Triglycerides (nmol/mg) 30.69 ± 3.76 29.59 ± 2.16
Values are expressed as means ± SEM; n = 10 mice per group.
*Indicates significant difference (p < 0.05) from control mice.
Lichtenstein et al. Nutrition & Metabolism 2013, 10:67 Page 3 of 7
http://www.nutritionandmetabolism.com/content/10/1/67Hepatic gene expression
Liver and whole intestine RNA isolation, reverse tran-
scription and real-time quantitative PCR analysis were
performed as previously described [5].
HDL functionality
HDL were isolated from mouse plasma, after precipitation
of apoB-containing lipoproteins with polyethylene glycol-
6000 [6]. Anti-oxidative property of HDL was assessed
by measuring the capacity of HDL to inhibit the oxidation
of native LDL as previously described [6,7]. Anti-inflamma-
tory property of HDL was evaluated on human umbilical
vein endothelial cells (HUVECs) by measuring MCP-1 gene
expression as previously described [6]. Efflux experiments
were performed by measuring cholesterol efflux for 5 hours
from primary mouse peritoneal macrophages towards
either plasma (1%, v/v) or apoB-depleted lipoproteins
(2%, v/v), as previously described [6].
Aortic sinus quantification
The lesions were estimated according to Paigen and col-
laborators [8] Briefly, each heart was frozen on a cryostat
mount with OCT compound (Tissue-Tek), and stored
at −80°C. Hearts were cut using a Leica CM3050S cryo-
stat. Fifty sections of 10-μm thickness were prepared from
the top of the left ventricle, where the aortic valves were
first visible, up to a position in the aorta where the valve
cusps were just disappearing from the field. After drying
for 1 hour, the sections were stained with oil red O and
counterstained with Mayer's hematoxylin. Five sections
out of the 50, each separated by 100 μm, were used for
specific morphometric evaluation of intimal lesions usingTable 3 Biliary lipid values in P2Y13
+/+ (WT) and P2Y13
−/−
mice fed a HCD for 16 weeks
WT P2Y13
−/−
Bile flow (μl/min/100 g BW) 5.58 ± 0.42 4.35 ± 0.26*
Cholesterol secretion (nmol/min/100 g BW) 3.79 ± 0.27 2.71 ± 0.36*
Bile acid secretion (nmol/min/100 g BW) 209.9 ± 16.0 167.1 ± 10.2*
Phospholipid secretion (nmol/min/100 g BW) 15.7 ± 0.2 9.7 ± 0.2*
Values are expressed as means ± SEM; n = 10 mice per group.
*Indicates significant difference (p < 0.05) from control mice.a computerized Leica image analysis system, consisting of
a Leica DMRE microscope coupled to a video camera and
Leica Qwin Imaging software (Leica Ltd, Cambridge, UK).
The first and most proximal section to the heart was taken
100 μm distal to the point where the aorta first becomes
rounded. Lipid droplets <500 μm2 as well as those located
in the media were excluded from the measurements. TheFigure 1 Lack of P2Y13 in mice fed HCD decreases in vivo
macrophage-to-feces reverse cholesterol transport. Two million
of 3H-cholesterol–labeled peritoneal macrophages from C57BL/6
donor mice were injected intraperitoneally in P2Y13
−/− (dark grey
squares and bars) and WT (light gray squares and bars) mice fed
HCD. (A) 3H-cholesterol appearance in plasma 6, 24, and 48 hours
after macrophage administration. (B), 3H-cholesterol tracer recovery
within liver 48 hours after macrophages injection. (C), 3H-cholesterol
appearance in feces collected continuously from 0 to 48 hours,
after macrophages injection. Data are expressed as percent cpm
injected ± SEM; n = 6 mice group. Statistically significant differences
from WT mice are indicated as *p < 0.05.
Table 4 Effect of HCD in P2Y13
−/− mice on hepatic mRNA expression of genes involved in lipid homeostasis
Gene Fold-change Accession N° Gene title
Scarb1 1.00 ± 0.12 0.86 ± 0.10 (p = 0.67) NM_016741 Scavenger receptor class B, member 1
Ldlr 1.00 ± 0.17 1.02 ± 0.15 (p = 0.75) NM_010700 Low density lipoprotein receptor
Abca1 1.00 ± 0.16 0.59 ± 0.05* (p = 0.04) NM_013454 ATP-binding cassette, sub-family A, member 1
Abcg1 1.00 ± 0.10 0.68 ± 0.07* (p = 0.02) NM_009593 ATP-binding cassette, sub-family G, member 1
Apoa1 1.00 ± 0.10 0.97 ± 0.07 (p = 0.72) NM_009692 Apolipoprotein A-I
Cyp7a1 1.00 ± 0.23 1.61 ± 0.24 (p = 0.06) NM_007824 Cytochrome P450, family 27, subfamily A, polypeptide 1
Cyp27a1 1.00 ± 0.13 1.11 ± 0.13 (p = 0.53) NM_024264 Cytochrome P450, family 8, subfamily B, polypeptide 1
Cyp8b1 1.00 ± 0.22 1.64 ± 0.26 (p = 0.18) NM_010012 Cytochrome P450, family 8, subfamily B, polypeptide 1
Abcg5 1.00 ± 0.12 0.64 ± 0.05* (p = 0.03) NM_031884 ATP-binding cassette, sub-family G, member 5
Abcg8 1.00 ± 0.10 0.61 ± 0.07** (p = 0.003) NM_026180 ATP-binding cassette, sub-family G, member 8
Abcb4 1.00 ± 0.07 0.74 ± 0.08 (p = 0.06) NM_008830 ATP-binding cassette, sub-family G, member 4
Abcb11/Bsep 1.00 ± 0.11 1.33 ± 0.10 (p = 0.22) NM_021022 ATP-binding cassette, sub-family B (MDR/TAP), member 11
Ntcp/Slc10a1 1.00± 0.22 1.51 ± 0.17 (p = 0.11) NM_011387 Solute carrier family 10 (sodium/bile acid
cotransporter family), member 1
Oatp/Slco1a1 1.00 ± 0.16 1.33 ± 0.19 (p = 0.47) NM_013797 Solute carrier organic anion transporter family, member 1A2
Hmgcr 1.00 ± 0.01 1.02 ± 0.09 (p = 0.44) NM_008255 3-hydroxy-3-methylglutaryl-Coenzyme A reductase
Srebp2 1.00 ± 0.09 0.74 ± 0.07 (p = 0.06) NM_033218 Sterol regulatory element binding transcription factor 2
Real-time PCR was performed on individual livers of 3 h fasted mice (n = 10 mice per group). For all genes, the fold change was calculated by dividing the P2Y13
−/−
mice value by the wild-type mice value (e.g. an increase of 80% from wild-type is reported as 1.80). * and ** indicate significant difference (p < 0.05 and p < 0.01
respectively) from wild-type mice.
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was used to evaluate the lesion size of each animal. The
coded slides were examined blind in two separate analyses
by the same examiner and gave consistent results (r = .97).
Statistical analysis
All results are presented as means ± SEM. Comparisons
between groups were made using the Mann–Whitney
test for independent samples. Outcomes of p < 0.05 were
considered significant. Analyses were performed using
GraphPad Prism 6 software.
Results and discussion
In order to investigate the role of P2Y13 receptor in a dys-
lipidemic context, we studied the phenotype of P2Y13
−/−Table 5 Effect of HCD in P2Y13
−/− mice on intestinal mRNA ex
Gene Fold-change Accessio
Npc1l1 1.00 ± 0.21 1.39 ± 0.21 (p = 0.36) NM_20
Abcg5 1.00 ± 0.26 1.53 ± 0.24 (p = 0.36) NM_02
Abcg8 1.00 ± 0.21 1.47 ± 0.19 (p = 0.18) NM_02
AbcA1 1.00 ± 0.15 1.52 ± 0.23 (p = 0.18) NM_01
Abcg1 1.00 ± 0.22 0.89 ± 0.11 (p = 0.94) NM_00
Scarb1 1.00 ± 0.25 1.41 ± 0.32 (p = 0.73) NM_01
Oatp/Slco1a1 1.00 ± 0.41 0.81 ± 0.17 (p = 0.94) NM_01
Fgf15 1.00 ± 0.28 1.09 ± 0.27 (p = 0.94) NM_00
Real-time PCR was performed on individual intestine of 3 h fasted mice (n = 6 mice
P2Y13.
−/− mice value by the wild-type mice value (e.g. an increase of 80% from wildmice fed high cholesterol diet (HCD) for 16 weeks.
Body weight and liver weight were unchanged between
P2Y13
−/− and wild-type (WT, C57BL/6) mice maintained
on HCD (data not shown) and plasma total cholesterol,
HDL-C, LDL-C and triglycerides did not differ either
(Table 1). However, on HCD feeding, hepatic total chol-
esterol content was significantly lower in P2Y13
−/− than
in WT mice, with decrease in both cholesterol ester and
free cholesterol (Table 2). To further assess the effect of
HCD on the metabolic phenotype of P2Y13
−/− mice, we
measured biliary flow and lipid secretion, which is consid-
ered an essential step in RCT [9]. As reported in Table 3,
biliary flow was significantly decreased and biliary secretion
of cholesterol, bile acid and phospholipid were also signifi-
cantly reduced in P2Y13
−/− as compared to WT mice afterpression of genes involved in lipid homeostasis
n N° Gene title
7242 Niemann-Pick C1-like protein 1
6180 ATP-binding cassette, sub-family G, member 5
6180 ATP-binding cassette, sub-family G, member 8
3454 ATP-binding cassette, sub-family A, member 1
9593 ATP-binding cassette, sub-family G, member 1
6741 Scavenger receptor class B, member 1
3797 Solute carrier organic anion transporter family, member 1A2
8003 Fibroblast growth factor 15
per group). For all genes, the fold change was calculated by dividing the
-type is reported as 1.80).
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3H-cholesterol from macrophages to the feces, which
is a surrogate well-established method to evaluate in vivo
RCT [10]. We observed that macrophage-to-feces RCT
was impaired in P2Y13
−/− as compared to WT mice, as
reflected by a ~60% reduction of total sterol recovered in
feces (Figure 1C, -53±5 and −78±4 in % of neutral sterols
and bile acids, respectively). This reduced RCT is mostA
C
Figure 2 P2Y13 deficiency does not change the functional properties
(A and B), protection of HUVECs against inflammation (C), protection of LD
mice per group. TBARS: Thiobarbituric aid reactive substances.likely attributable to the described function of P2Y13
receptor in hepatic HDL uptake [4,11]. Accordingly,
P2Y13
−/− mice fed HCD displayed a significant higher
3H- tracer present in plasma at 6 and 24 h (Figure 1A)
and a trend to lower 3H-tracer recovered in the liver at
48 h, as compared to WT mice (Figure 1B). Macrophage-
to-feces RCT experiments have frequently reported that
3H-tracer recovered in feces is more sensitive to evidenceB
D
of HDL on HCD. HDL function was determined as cholesterol efflux
L against oxidation (D). Data are presented as means ± SEM, n = 10
Figure 3 P2Y13 deficiency does not induce atherosclerosis
development on HCD. Aortic sinus sections were stained with oil
red O and lipid content was quantified. Data are presented as
means ± SEM, n = 6 in WT group, and n = 9 in P2Y13
−/− group.
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liver which is often unchanged [10,12], probably because
radioactivity recovered in feces represents the endpoint of
RCT whereas radioactivity present in plasma and liver de-
pends on cholesterol flux of a freely distributable tracer.
This hence might explain the unchanged % of 3H-tracer
present in plasma at 48 h and the lack of a significance in
the decrease of 3H-tracer in the liver of P2Y13
−/− compared
to WT mice (Figure 1A, B).
P2Y13 deficiency results in a ~40% decrease of hepatic
messenger RNA (mRNA) expression of the heterodimeric
ATP-binding transporter Abcg5 and Abcg8 (Table 4),
suggesting that the cholesterol derived from HDL that
has been internalized through P2Y13 receptor might use
the Abcg5/g8 dependent pathway for apical biliary choles-
terol secretion [13]. Hepatic gene expression of the other
transporters controlling bile acid and phospholipid fluxes
in the liver, such as biliary phospholipid transport protein
(Abcb4/mdr3), bile salt export pump (Abcb11/bsep),
basolateral transporter sodium taurocholate cotransporting
polypeptide (Ntcp) and organic anion transport polypeptide
(Oatp) were unchanged (Table 4). As reported in Tables 4
and 5, there was also no significant change in the expres-
sion of gene controlling bile acid production such as
hepatic cholesterol 7 alpha-hydroxylase (Cyp7A1), hepatic
sterol 27-hydroxylase (Cyp27A1), hepatic sterol 12-alpha-
hydroxylase (Cyp8b1) and intestinal Fibroblast growth
factor 15 (Fgf15). Furthermore, the reduction of bile acid
secretion observed in P2Y13
−/− mice compared to WT mice
was mainly driven by lower bile flow (Table 3) since the
concentration of bile acid in bile was not significantly
reduced (data not shown) whereas both secretion and
concentration of biliary cholesterol and phospholipid were
decreased (Table 3 and data not shown). Altogether these
data indicate that the effect of P2Y13 deficiency on decreas-
ing bile acid secretion into the bile cannot be attributed to
a decrease of hepatic bile acids synthesis or apical transport
but is more likely driven by the decrease of biliary flow.
However, further investigation is required to determine the
mechanism by which P2Y13-mediated HDL endocytosis
regulates biliary lipid secretion process. Indeed, although
recent studies evidenced that HDL internalized by hepato-
cytes are transported to two intracellular pools – a rapid
turnover retroendocytic pool involving endosomal recycling
compartment (ERC) and a slow-turnover pool, involving
multivesicular bodies, that is eventually further transported
to lysosomes for degradation [14], the process by which
intracellular HDL trafficking governs biliary lipid secretion
is still poorly characterized.
Interestingly, hepatic mRNA expression of Abca1 and
Abcg1, which contribute to cellular cholesterol efflux
towards lipid-poor ApoA-I and HDL particles, respectively
[13], was significantly decreased in P2Y13
−/− mice after
16 weeks of HCD (Table 4). These results might suggestthat the decrease of hepatobiliary cholesterol secretion
observed in P2Y13
−/− mice fed a HCD is associated with a
decrease of de novo HDL formation, thus explaining
the unchanged plasma HDL-C levels per se, as previously
proposed for P2Y13
−/− mice fed a chow diet [4]. Alterna-
tively, the P2Y13-mediated HDL endocytosis pathway might
efficiently drive cholesterol from HDL towards biliary lipid
secretion but could be quantitatively negligible regarding
the steady state concentration of plasma HDL-C. Accord-
ingly, it is now well established that macrophage-derived
cholesterol represents only a minor proportion of the total
cholesterol transported by HDL particles but is essential
to prevent foam cell formation [15] supporting the concept
that the dynamics of HDL particles are essential for
RCT but not necessary correlated to the static measure of
plasma HDL-C concentration.
To assess HDL functionality in these mice, we tested
whether P2Y13 deletion would influence HDL func-
tionalities regarding either their anti-inflammatory or
anti-oxidative properties, or their capacity to elicit efflux
from cholesterol-loaded macrophages. However, P2Y13-
deficient mice did not show any change in these respective
HDL functionalities after 16 weeks of HCD (Figure 2),
suggesting that P2Y13 deletion neither interferes with
HDL pleiotropic functions, nor HDL-mediated efflux from
cholesterol-loaded macrophages. Furthermore, feeding the
HCD for 16 weeks did not result in an increased lipid
deposition in the aortic sinus of P2Y13
−/− compared to WT
mice (Figure 3). Not surprisingly, these results indicate
that P2Y13 deletion in C57BL/6 mice does not initiate ath-
erosclerosis development. To formally assess the hypothesis
whether P2Y13 receptor plays a role in atherosclerosis
development, mice lacking P2Y13 would have to be crossed
with a proatherogenic mouse model.
We previously demonstrated that chow-fed P2Y13 defi-
cient mice displayed a reduced uptake of HDL by the liver
associated to decreased hepatic free cholesterol content
and impaired biliary secretion of cholesterol and phos-
pholipids [4]. These metabolic changes translated into a
substantial ~45% decrease in the rate of macrophage-to-
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chronic high cholesterol intake accentuates this metabolic
phenotype, with a more dramatic impaired hepatobiliary
RCT. Indeed, using HCD-fed P2Y13
−/− compared to WT
mice, we reported here that both free and esterified choles-
terol content in the liver were decreased (Table 2), together
with biliary flow and biliary lipid secretion (Table 3) and
a ~60% reduction in the rate of macrophage-to-feces
RCT (Figure 1).
P2Y13 receptor is also expressed in the intestine [16]
and could potentially also regulate intestinal cholesterol
absorption or excretion. Our results indicates that the
mRNA expression level of the principal genes involved in
cholesterol absorption were unchanged between P2Y13
−/−
and WT mice maintained on HCD (Table 5), suggesting
that cholesterol absorption is unchanged in P2Y13
−/− mice.
Overall, our work emphasizes the importance of hepatic
P2Y13 activity when diet is rich in cholesterol, by regulating
biliary lipid output and overall RCT without affecting
HDL-C level per se or selected HDL functions. Thus, this
study opens the way to reconsider pharmacological ap-
proaches to target HDL metabolism, particularly with
regard to mechanistic aspects of RCT, by improving the
flux of circulating HDL towards the liver (e.g., by stimulat-
ing P2Y13) rather than increasing plasma HDL-C levels.
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